Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary intervention
- PMID: 24964369
- PMCID: PMC4130236
- DOI: 10.1021/bm5007757
Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary intervention
Abstract
Cardiovascular disease remains one of the largest contributors to death worldwide. Improvements in cardiovascular technology leading to the current generation of drug-eluting stents, bioresorbable stents, and drug-eluting balloons, coupled with advances in antirestenotic therapeutics developed by pharmaceutical community, have had a profound impact on quality of life and longevity. However, these procedures and devices contribute to both short- and long-term complications. Thus, room for improvement and development of new, alternative strategies exists. Two major approaches have been investigated to improve outcomes following percutaneous coronary intervention including perivascular delivery and luminal paving. For both approaches, polymers play a major role as controlled research vehicles, carriers for cells, and antithrombotic coatings. With improvements in catheter delivery devices and increases in our understanding of the biology of healthy and diseased vessels, the time is ripe for development of novel macromolecular coatings that can protect the vessel lumen following balloon angioplasty and promote healthy vascular healing.
Figures

Similar articles
-
Local drug delivery to prevent restenosis.J Vasc Surg. 2013 May;57(5):1403-14. doi: 10.1016/j.jvs.2012.12.069. J Vasc Surg. 2013. PMID: 23601595 Free PMC article. Review.
-
Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy.Circ J. 2011;75(6):1287-96. doi: 10.1253/circj.cj-11-0366. Epub 2011 Apr 29. Circ J. 2011. PMID: 21532177 Review.
-
INtimal hyPerplasia evAluated by oCT in de novo COROnary lesions treated by drug-eluting balloon and bare-metal stent (IN-PACT CORO): study protocol for a randomized controlled trial.Trials. 2012 May 6;13:55. doi: 10.1186/1745-6215-13-55. Trials. 2012. PMID: 22559260 Free PMC article. Clinical Trial.
-
Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.Cardiovasc Revasc Med. 2017 Dec;18(8):596-600. doi: 10.1016/j.carrev.2017.05.018. Epub 2017 May 31. Cardiovasc Revasc Med. 2017. PMID: 28625402 Clinical Trial.
-
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008. Epub 2013 Dec 11. JACC Cardiovasc Interv. 2014. PMID: 24332420 Clinical Trial.
Cited by
-
A vascular smooth muscle cell X-box binding protein 1 and transglutaminase 2 regulatory circuit limits neointimal hyperplasia.PLoS One. 2019 Apr 3;14(4):e0212235. doi: 10.1371/journal.pone.0212235. eCollection 2019. PLoS One. 2019. PMID: 30943188 Free PMC article.
-
Inhibition of monocyte-like cell extravasation protects from neurodegeneration in DBA/2J glaucoma.Mol Neurodegener. 2019 Jan 22;14(1):6. doi: 10.1186/s13024-018-0303-3. Mol Neurodegener. 2019. PMID: 30670050 Free PMC article.
-
Long-term outcomes of conservative treatment and endovascular treatment in patients with symptomatic spontaneous isolated superior mesenteric artery dissection: a single-center experience.BMC Cardiovasc Disord. 2020 May 29;20(1):256. doi: 10.1186/s12872-020-01532-y. BMC Cardiovasc Disord. 2020. PMID: 32471346 Free PMC article.
-
A role for proteoglycans in vascular disease.Matrix Biol. 2018 Oct;71-72:396-420. doi: 10.1016/j.matbio.2018.02.019. Epub 2018 Feb 27. Matrix Biol. 2018. PMID: 29499356 Free PMC article. Review.
-
Nitric Oxide-Producing Cardiovascular Stent Coatings for Prevention of Thrombosis and Restenosis.Front Bioeng Biotechnol. 2020 Jun 24;8:578. doi: 10.3389/fbioe.2020.00578. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 32671029 Free PMC article. Review.
References
-
- Association A. H.Heart Disease and Stroke Statistics - 2010 Update; American Heart Association: Dallas, TX, 2010.
-
- Grϋntzig A. Lancet 1978, 3118058263. - PubMed
-
- Buie V. C.; Owings M. F.; DeFrances C. J.; Golosinskiy A.. National Hospital Discharge Survey: 2006 Summary; National Center For Health Statistics: Hyattsville, MD, 2010; Vol. 13. - PubMed
-
- Lloyd-Jones D.; Adams R.; Carnethon M.; De Simone G.; Ferguson T. B.; Flegal K.; Ford E.; Furie K.; Go A.; Greenlund K.; Haase N.; Hailpern S.; Ho M.; Howard V.; Kissela B.; Kittner S.; Lackland D.; Lisabeth L.; Marelli A.; McDermott M.; Meigs J.; Mozaffarian D.; Nichol G.; O’Donnell C.; Roger V.; Rosamond W.; Sacco R.; Sorlie P.; Stafford R.; Steinberger J.; Thom T.; Wasserthiel-Smoller S.; Wong N.; Wylie-Rosett J.; Hong Y. Circulation 2008, 119, 1–161. - PubMed
-
- Go A. S.; Mozaffarian D.; Roger V. L.; Benjamin E. J.; Berry J. D.; Borden W. B.; Bravata D. M.; Dai S.; Ford E. S.; Fox C. S.; Franco S.; Fullerton H. J.; Gillespie C.; Hailpern S. M.; Heit J. A.; Howard V. J.; Huffman M. D.; Kissela B. M.; Kittner S. J.; Lackland D. T.; Lichtman J. H.; Lisabeth L. D.; Magid D.; Marcus G. M.; Marelli A.; Matchar D. B.; McGuire D. K.; Mohler E. R.; Moy C. S.; Mussolino M. E.; Nichol G.; Paynter N. P.; Schreiner P. J.; Sorlie P. D.; Stein J.; Turan T. N.; Virani S. S.; Wong N. D.; Woo D.; Turner M. B. Circulation 2013, 127, e6–e245. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical